Evaluation of nanoparticle immunotoxicity.
The pharmaceutical industry is developing increasing numbers of drugs and diagnostics based on nanoparticles, and evaluating the immune response to these diverse formulations has become a challenge for scientists and regulatory agencies alike. An international panel of scientists and representatives from various agencies and companies reviewed the imitations of current tests at a workshop held at the National Cancer Institute in Frederick, Maryland. This article outlines practical strategies for identifying and controlling interferences in common evaluation methods and the implications for regulation.
Dobrovolskaia
Marina A
MA
Nanotechnology Characterization Laboratory, SAIC-Frederick Inc., NCI-Frederick, Frederick, Maryland 21702, USA. marina@mail.nih.gov
Germolec
Dori R
DR
Weaver
James L
JL
D019411:Clinical Laboratory Techniques / Q000592:standards; D004345:Drug Industry / Q000592:standards; D000922:Immunotoxins / Q000633:toxicity; D008033:Limulus Test; D053758:Nanoparticles / Q000633:toxicity*; D018675:Toxicity Tests / Q000379:methods* / Q000592:standards
D000922:Immunotoxins